Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: January 3, 2026, 11:14 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 539524 | NSE: LALPATHLAB

Dr Lal Pathlabs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: January 3, 2026, 11:14 am

Market Cap 24,700 Cr.
Current Price 1,474
High / Low 1,771/1,147
Stock P/E46.2
Book Value 142
Dividend Yield0.81 %
ROCE28.9 %
ROE24.3 %
Face Value 10.0
PEG Ratio5.10

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Dr Lal Pathlabs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
NG Industries Ltd 51.4 Cr. 154 187/12010.5 1172.28 %23.6 %20.7 % 10.0
Global Longlife Hospital and Research Ltd 24.1 Cr. 23.0 35.5/15.5 24.30.00 %13.7 %17.7 % 10.0
Gian Lifecare Ltd 9.04 Cr. 8.74 20.8/7.08100 19.10.00 %3.00 %0.81 % 10.0
Fortis Malar Hospitals Ltd 113 Cr. 60.1 98.7/55.224.9 18.30.00 %0.83 %0.56 % 10.0
Family Care Hospitals Ltd 20.1 Cr. 3.72 6.94/3.40 1.510.00 %79.2 %85.5 % 10.0
Industry Average26,425.21 Cr698.6193.3993.180.32%15.48%14.81%9.04

All Competitor Stocks of Dr Lal Pathlabs Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 534489491541601539545602660597603670731
Expenses 390376375395424398401432458443434478506
Operating Profit 144113116146178141145170202154169192224
OPM % 27%23%24%27%30%26%27%28%31%26%28%29%31%
Other Income 9101414181818212225262825
Interest 11998877665555
Depreciation 39383835363637353536363540
Profit before tax 1037683118152116120150183138153181204
Tax % 30%30%32%29%27%29%28%28%29%29%-1%26%25%
Net Profit 72545784111828610813198156134152
EPS in Rs 4.303.173.404.956.554.875.066.377.735.789.267.908.97

Last Updated: January 1, 2026, 10:04 pm

Below is a detailed analysis of the quarterly data for Dr Lal Pathlabs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Sales, as of Sep 2025, the value is 731.00 Cr.. The value appears strong and on an upward trend. It has increased from 670.00 Cr. (Jun 2025) to 731.00 Cr., marking an increase of 61.00 Cr..
  • For Expenses, as of Sep 2025, the value is 506.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 478.00 Cr. (Jun 2025) to 506.00 Cr., marking an increase of 28.00 Cr..
  • For Operating Profit, as of Sep 2025, the value is 224.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Jun 2025) to 224.00 Cr., marking an increase of 32.00 Cr..
  • For OPM %, as of Sep 2025, the value is 31.00%. The value appears strong and on an upward trend. It has increased from 29.00% (Jun 2025) to 31.00%, marking an increase of 2.00%.
  • For Other Income, as of Sep 2025, the value is 25.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Jun 2025) to 25.00 Cr., marking a decrease of 3.00 Cr..
  • For Interest, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 5.00 Cr..
  • For Depreciation, as of Sep 2025, the value is 40.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 35.00 Cr. (Jun 2025) to 40.00 Cr., marking an increase of 5.00 Cr..
  • For Profit before tax, as of Sep 2025, the value is 204.00 Cr.. The value appears strong and on an upward trend. It has increased from 181.00 Cr. (Jun 2025) to 204.00 Cr., marking an increase of 23.00 Cr..
  • For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 25.00%, marking a decrease of 1.00%.
  • For Net Profit, as of Sep 2025, the value is 152.00 Cr.. The value appears strong and on an upward trend. It has increased from 134.00 Cr. (Jun 2025) to 152.00 Cr., marking an increase of 18.00 Cr..
  • For EPS in Rs, as of Sep 2025, the value is 8.97. The value appears strong and on an upward trend. It has increased from 7.90 (Jun 2025) to 8.97, marking an increase of 1.07.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 5:26 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 5586607919121,0571,2031,3301,5812,0872,0172,2272,4612,600
Expenses 4195045826757939109871,1451,5261,5271,6171,7641,860
Operating Profit 139156210238264294344436561490609698739
OPM % 25%24%26%26%25%24%26%28%27%24%27%28%28%
Other Income 81220273146555152426991104
Interest 00011115163038292220
Depreciation 2728282833387377108150144142147
Profit before tax 119140201237261301310394475344505625676
Tax % 33%31%34%34%34%33%27%25%26%30%28%21%
Net Profit 8096133156172200228296350241362492540
EPS in Rs 148.2717.5115.9918.6120.4923.9027.1134.9941.3728.6542.8558.2863.84
Dividend Payout % 7%9%15%16%22%25%44%57%29%42%56%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)20.00%38.54%17.29%10.26%16.28%14.00%29.82%18.24%-31.14%50.21%35.91%
Change in YoY Net Profit Growth (%)0.00%18.54%-21.25%-7.04%6.02%-2.28%15.82%-11.58%-49.39%81.35%-14.30%

Dr Lal Pathlabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:14%
5 Years:13%
3 Years:6%
TTM:11%
Compounded Profit Growth
10 Years:18%
5 Years:17%
3 Years:12%
TTM:35%
Stock Price CAGR
10 Years:%
5 Years:12%
3 Years:11%
1 Year:-3%
Return on Equity
10 Years:23%
5 Years:22%
3 Years:20%
Last Year:24%

Last Updated: September 5, 2025, 3:10 am

Balance Sheet

Last Updated: December 10, 2025, 2:36 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 54558383838383838383838484
Reserves 1512604255127058629491,1621,4251,5831,7662,0892,304
Borrowings 2827000000533420247157156
Other Liabilities 11913411895128145341415309297357383415
Total Liabilities 3524756256909161,0911,3741,6612,3492,3832,4542,7132,959
Fixed Assets 1401501661522082094134471,3751,3051,2281,1681,232
CWIP 0141810311101556317
Investments 938641061451851645965150114327486
Other Assets 2032863914145546947861,1448939231,1071,2151,225
Total Assets 3524756256909161,0911,3741,6612,3492,3832,4542,7132,959

Below is a detailed analysis of the balance sheet data for Dr Lal Pathlabs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 84.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 84.00 Cr..
  • For Reserves, as of Sep 2025, the value is 2,304.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,089.00 Cr. (Mar 2025) to 2,304.00 Cr., marking an increase of 215.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 156.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 157.00 Cr. (Mar 2025) to 156.00 Cr., marking a decrease of 1.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 415.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 383.00 Cr. (Mar 2025) to 415.00 Cr., marking an increase of 32.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 2,959.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,713.00 Cr. (Mar 2025) to 2,959.00 Cr., marking an increase of 246.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 1,232.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,168.00 Cr. (Mar 2025) to 1,232.00 Cr., marking an increase of 64.00 Cr..
  • For CWIP, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 14.00 Cr..
  • For Investments, as of Sep 2025, the value is 486.00 Cr.. The value appears strong and on an upward trend. It has increased from 327.00 Cr. (Mar 2025) to 486.00 Cr., marking an increase of 159.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 1,225.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,215.00 Cr. (Mar 2025) to 1,225.00 Cr., marking an increase of 10.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 2,959.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,713.00 Cr. (Mar 2025) to 2,959.00 Cr., marking an increase of 246.00 Cr..

Notably, the Reserves (2,304.00 Cr.) exceed the Borrowings (156.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +98122159171197219284398447456535569
Cash from Investing Activity +-89-113-163-137-172-100-26-212-449-287-24-303
Cash from Financing Activity +-10-10-3213-55-190-139136-283-414-334
Net Cash Flow-28-5237646748134-11497-68

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow111.00129.00210.00238.00264.00294.00344.00436.0028.0070.00362.00541.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days161717171416141515131313
Inventory Days3731334440703938283027
Days Payable908997106111144132107127151151
Cash Conversion Cycle16-35-42-47-47-55-60-78-54-87-108-110
Working Capital Days-26-92719170-19-17-54-56-46-30
ROCE %60%48%47%43%38%35%32%33%29%18%25%29%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters55.04%55.03%55.01%54.61%54.60%54.60%54.60%53.92%53.91%53.91%53.79%53.21%
FIIs25.80%24.89%23.27%24.35%25.36%26.15%25.43%26.82%26.82%23.90%21.69%21.86%
DIIs6.20%6.56%8.34%8.85%9.27%9.40%12.42%12.60%12.88%15.79%17.62%18.22%
Government0.00%0.00%0.29%0.29%0.29%0.29%0.29%0.29%0.29%0.29%0.29%0.27%
Public12.38%13.01%12.65%11.48%10.12%9.24%6.95%6.02%5.82%5.84%6.22%6.07%
Others0.56%0.51%0.44%0.41%0.37%0.32%0.30%0.33%0.28%0.27%0.39%0.37%
No. of Shareholders1,79,6361,80,1631,74,4441,60,6791,49,9011,46,7411,31,1891,16,6061,16,2361,15,6991,18,6561,12,703

Shareholding Pattern Chart

No. of Shareholders

Dr Lal Pathlabs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Flexi Cap Fund 2,000,000 0.65 610.36N/AN/AN/A
UTI Flexi Cap Fund 1,200,626 1.43 366.411,200,7222025-12-15 01:57:00-0.01%
Aditya Birla Sun Life Flexi Cap Fund 823,007 1.01 251.17N/AN/AN/A
SBI Large & Midcap Fund 650,000 0.54 198.37650,0002025-04-22 03:10:340%
Nippon India Small Cap Fund 645,485 0.29 196.99N/AN/AN/A
Nippon India Pharma Fund 609,112 2.2 185.89425,0002025-12-08 04:19:4243.32%
HDFC ELSS Tax Saver Fund 570,000 1.01 173.95539,8002025-12-08 01:28:365.59%
Sundaram Mid Cap Fund 519,351 1.19 158.5N/AN/AN/A
Nippon India Multi Cap Fund 417,494 0.25 127.41N/AN/AN/A
UTI Mid Cap Fund 390,563 0.99 119.19529,7302025-12-08 01:18:34-26.27%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 58.4843.0528.8241.7035.33
Diluted EPS (Rs.) 58.4042.9828.7441.7035.25
Cash EPS (Rs.) 75.8660.6046.9355.0044.83
Book Value[Excl.RevalReserv]/Share (Rs.) 259.92225.85203.86185.20153.10
Book Value[Incl.RevalReserv]/Share (Rs.) 259.92225.85203.86185.20153.10
Revenue From Operations / Share (Rs.) 294.45266.73241.93250.45189.72
PBDIT / Share (Rs.) 94.3981.2763.7673.5858.51
PBIT / Share (Rs.) 77.4164.0645.7460.6149.24
PBT / Share (Rs.) 74.7460.5541.2456.9947.32
Net Profit / Share (Rs.) 58.8943.4028.9242.0335.57
NP After MI And SOA / Share (Rs.) 58.2742.8528.6541.3734.99
PBDIT Margin (%) 32.0530.4626.3529.3730.83
PBIT Margin (%) 26.2924.0118.9024.2025.95
PBT Margin (%) 25.3822.7017.0422.7524.94
Net Profit Margin (%) 19.9916.2711.9516.7818.74
NP After MI And SOA Margin (%) 19.7916.0611.8416.5118.44
Return on Networth / Equity (%) 22.4219.3414.3322.8623.42
Return on Capital Employeed (%) 27.9526.8619.9027.2529.58
Return On Assets (%) 17.9314.5610.0114.6517.55
Long Term Debt / Equity (X) 0.000.000.050.110.00
Total Debt / Equity (X) 0.000.040.140.220.00
Asset Turnover Ratio (%) 0.950.910.850.961.01
Current Ratio (X) 3.392.422.071.754.18
Quick Ratio (X) 3.302.342.001.654.02
Inventory Turnover Ratio (X) 67.030.000.000.000.00
Dividend Payout Ratio (NP) (%) 41.0355.7641.6233.5533.98
Dividend Payout Ratio (CP) (%) 31.7739.7825.5525.5426.87
Earning Retention Ratio (%) 58.9744.2458.3866.4566.02
Cash Earning Retention Ratio (%) 68.2360.2274.4574.4673.13
Interest Coverage Ratio (X) 35.3723.1114.1620.3230.47
Interest Coverage Ratio (Post Tax) (X) 23.0713.347.4212.6119.53
Enterprise Value (Cr.) 19910.0218177.2514843.3421493.2321670.29
EV / Net Operating Revenue (X) 8.098.167.3610.3013.70
EV / EBITDA (X) 25.2326.7927.9235.0544.44
MarketCap / Net Operating Revenue (X) 8.428.487.5610.4114.27
Retention Ratios (%) 58.9644.2358.3766.4466.01
Price / BV (X) 9.5310.219.1514.4118.12
Price / Net Operating Revenue (X) 8.428.487.5610.4114.27
EarningsYield 0.020.010.010.010.01

After reviewing the key financial ratios for Dr Lal Pathlabs Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 58.48. This value is within the healthy range. It has increased from 43.05 (Mar 24) to 58.48, marking an increase of 15.43.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 58.40. This value is within the healthy range. It has increased from 42.98 (Mar 24) to 58.40, marking an increase of 15.42.
  • For Cash EPS (Rs.), as of Mar 25, the value is 75.86. This value is within the healthy range. It has increased from 60.60 (Mar 24) to 75.86, marking an increase of 15.26.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 259.92. It has increased from 225.85 (Mar 24) to 259.92, marking an increase of 34.07.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 259.92. It has increased from 225.85 (Mar 24) to 259.92, marking an increase of 34.07.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 294.45. It has increased from 266.73 (Mar 24) to 294.45, marking an increase of 27.72.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 94.39. This value is within the healthy range. It has increased from 81.27 (Mar 24) to 94.39, marking an increase of 13.12.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 77.41. This value is within the healthy range. It has increased from 64.06 (Mar 24) to 77.41, marking an increase of 13.35.
  • For PBT / Share (Rs.), as of Mar 25, the value is 74.74. This value is within the healthy range. It has increased from 60.55 (Mar 24) to 74.74, marking an increase of 14.19.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 58.89. This value is within the healthy range. It has increased from 43.40 (Mar 24) to 58.89, marking an increase of 15.49.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 58.27. This value is within the healthy range. It has increased from 42.85 (Mar 24) to 58.27, marking an increase of 15.42.
  • For PBDIT Margin (%), as of Mar 25, the value is 32.05. This value is within the healthy range. It has increased from 30.46 (Mar 24) to 32.05, marking an increase of 1.59.
  • For PBIT Margin (%), as of Mar 25, the value is 26.29. This value exceeds the healthy maximum of 20. It has increased from 24.01 (Mar 24) to 26.29, marking an increase of 2.28.
  • For PBT Margin (%), as of Mar 25, the value is 25.38. This value is within the healthy range. It has increased from 22.70 (Mar 24) to 25.38, marking an increase of 2.68.
  • For Net Profit Margin (%), as of Mar 25, the value is 19.99. This value exceeds the healthy maximum of 10. It has increased from 16.27 (Mar 24) to 19.99, marking an increase of 3.72.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 19.79. This value is within the healthy range. It has increased from 16.06 (Mar 24) to 19.79, marking an increase of 3.73.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 22.42. This value is within the healthy range. It has increased from 19.34 (Mar 24) to 22.42, marking an increase of 3.08.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 27.95. This value is within the healthy range. It has increased from 26.86 (Mar 24) to 27.95, marking an increase of 1.09.
  • For Return On Assets (%), as of Mar 25, the value is 17.93. This value is within the healthy range. It has increased from 14.56 (Mar 24) to 17.93, marking an increase of 3.37.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.00, marking a decrease of 0.04.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.95. It has increased from 0.91 (Mar 24) to 0.95, marking an increase of 0.04.
  • For Current Ratio (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.39, marking an increase of 0.97.
  • For Quick Ratio (X), as of Mar 25, the value is 3.30. This value exceeds the healthy maximum of 2. It has increased from 2.34 (Mar 24) to 3.30, marking an increase of 0.96.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 67.03. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 67.03, marking an increase of 67.03.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 41.03. This value is within the healthy range. It has decreased from 55.76 (Mar 24) to 41.03, marking a decrease of 14.73.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 31.77. This value is within the healthy range. It has decreased from 39.78 (Mar 24) to 31.77, marking a decrease of 8.01.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 58.97. This value is within the healthy range. It has increased from 44.24 (Mar 24) to 58.97, marking an increase of 14.73.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 68.23. This value is within the healthy range. It has increased from 60.22 (Mar 24) to 68.23, marking an increase of 8.01.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 35.37. This value is within the healthy range. It has increased from 23.11 (Mar 24) to 35.37, marking an increase of 12.26.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 23.07. This value is within the healthy range. It has increased from 13.34 (Mar 24) to 23.07, marking an increase of 9.73.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 19,910.02. It has increased from 18,177.25 (Mar 24) to 19,910.02, marking an increase of 1,732.77.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.09. This value exceeds the healthy maximum of 3. It has decreased from 8.16 (Mar 24) to 8.09, marking a decrease of 0.07.
  • For EV / EBITDA (X), as of Mar 25, the value is 25.23. This value exceeds the healthy maximum of 15. It has decreased from 26.79 (Mar 24) to 25.23, marking a decrease of 1.56.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.42. This value exceeds the healthy maximum of 3. It has decreased from 8.48 (Mar 24) to 8.42, marking a decrease of 0.06.
  • For Retention Ratios (%), as of Mar 25, the value is 58.96. This value is within the healthy range. It has increased from 44.23 (Mar 24) to 58.96, marking an increase of 14.73.
  • For Price / BV (X), as of Mar 25, the value is 9.53. This value exceeds the healthy maximum of 3. It has decreased from 10.21 (Mar 24) to 9.53, marking a decrease of 0.68.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.42. This value exceeds the healthy maximum of 3. It has decreased from 8.48 (Mar 24) to 8.42, marking a decrease of 0.06.
  • For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Dr Lal Pathlabs Ltd as of January 5, 2026 is: ₹1,285.67

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of January 5, 2026, Dr Lal Pathlabs Ltd is Overvalued by 12.78% compared to the current share price ₹1,474.00

Intrinsic Value of Dr Lal Pathlabs Ltd as of January 5, 2026 is: ₹1,402.20

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of January 5, 2026, Dr Lal Pathlabs Ltd is Overvalued by 4.87% compared to the current share price ₹1,474.00

Last 5 Year EPS CAGR: 9.06%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 36.42%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -16.17, which is a positive sign.
  3. The stock has a low average Cash Conversion Cycle of -58.92, which is a positive sign.
  4. The company has higher reserves (1,091.77 cr) compared to borrowings (120.62 cr), indicating strong financial stability.
  5. The company has shown consistent growth in sales (225.77 cr) and profit (352.92 cr) over the years.

    Stock Analysis

    • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Lal Pathlabs Ltd:
      1. Net Profit Margin: 19.99%
        • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
      2. ROCE: 27.95% (Industry Average ROCE: 15.48%)
        • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
      3. ROE%: 22.42% (Industry Average ROE: 14.81%)
        • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
      4. Interest Coverage Ratio (Post Tax): 23.07
        • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
      5. Quick Ratio: 3.3
        • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
      6. Stock P/E: 46.2 (Industry average Stock P/E: 93.39)
        • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
      7. Total Debt / Equity: 0
        • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
      The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
      Stock Rating:

    About the Company - Qualitative Analysis

    Dr. Lal Pathlabs Ltd. is a Public Limited Listed company incorporated on 14/02/1995 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L74899DL1995PLC065388 and registration number is 065388. Currently Company is involved in the business activities of Other human health activities. Company's Total Operating Revenue is Rs. 2351.62 Cr. and Equity Capital is Rs. 83.59 Cr. for the Year ended 31/03/2025.
    INDUSTRYADDRESSCONTACT
    Hospitals & Medical ServicesBlock E, New Delhi Delhi 110085Contact not found
    Management
    NamePosition Held
    Brig.(Hony) Dr. Arvind LalExecutive Chairman
    Dr. Vandana LalWhole Time Director
    Dr. Archana Lal ErdmannNon Executive Director
    Mr. Rahul SharmaNon Executive Director
    Mr. Arun DuggalIndependent Director
    Mr. Gurinder Singh KalraIndependent Director
    Mr. Rajit MehtaIndependent Director
    Mrs. Somya SatsangiIndependent Director
    Mr. Rohit BhasinIndependent Director

    FAQ

    What is the intrinsic value of Dr Lal Pathlabs Ltd?

    Dr Lal Pathlabs Ltd's intrinsic value (as of 05 January 2026) is ₹1285.67 which is 12.78% lower the current market price of ₹1,474.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹24,700 Cr. market cap, FY2025-2026 high/low of ₹1,771/1,147, reserves of ₹2,304 Cr, and liabilities of ₹2,959 Cr.

    What is the Market Cap of Dr Lal Pathlabs Ltd?

    The Market Cap of Dr Lal Pathlabs Ltd is 24,700 Cr..

    What is the current Stock Price of Dr Lal Pathlabs Ltd as on 05 January 2026?

    The current stock price of Dr Lal Pathlabs Ltd as on 05 January 2026 is ₹1,474.

    What is the High / Low of Dr Lal Pathlabs Ltd stocks in FY 2025-2026?

    In FY 2025-2026, the High / Low of Dr Lal Pathlabs Ltd stocks is ₹1,771/1,147.

    What is the Stock P/E of Dr Lal Pathlabs Ltd?

    The Stock P/E of Dr Lal Pathlabs Ltd is 46.2.

    What is the Book Value of Dr Lal Pathlabs Ltd?

    The Book Value of Dr Lal Pathlabs Ltd is 142.

    What is the Dividend Yield of Dr Lal Pathlabs Ltd?

    The Dividend Yield of Dr Lal Pathlabs Ltd is 0.81 %.

    What is the ROCE of Dr Lal Pathlabs Ltd?

    The ROCE of Dr Lal Pathlabs Ltd is 28.9 %.

    What is the ROE of Dr Lal Pathlabs Ltd?

    The ROE of Dr Lal Pathlabs Ltd is 24.3 %.

    What is the Face Value of Dr Lal Pathlabs Ltd?

    The Face Value of Dr Lal Pathlabs Ltd is 10.0.

    Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Dr Lal Pathlabs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
    Explore More Stocks